In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Sending letters to encourage guideline-directed practice in the management of chronic kidney disease to either patients or ...

A spirited pro/con debate at ERA 2025 explores whether population-level albuminuria screening could improve early CKD detection, with feasibility, cost-effectiveness, and equity all weighed.

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...

Originally designed as glucose-lowering medications, SGLT2 inhibitors provide benefits across the cardio-renal-metabolic ...

BEIJING--(BUSINESS WIRE)--Novo Holdings, a leading global life science investor, and KKR, a leading global investment firm, today announced the signing of definitive agreements under which Novo ...